Dr. Scott D. Perrapato, DO

Dr. Perrapato practices at University of Vermont Medical Center in Burlington, Vermont, part of University of Vermont Health Network.

Dr. Perrapato's NPI, 1326034992, was assigned on September 20, 2005. Dr. Perrapato graduated from Rowan University School of Osteopathic Medicine in 1982. Dr. Perrapato holds New York license 168929.

Dr. Perrapato's primary practice is University of Vermont Medical Center, at 111 Colchester Ave, Burlington, VT 05401 in Chittenden County. The practice phone is (802) 847-0000.

Dr. Perrapato's primary practice is University of Vermont Medical Center in Burlington, Vermont, part of University of Vermont Health Network. Dr. Perrapato is also affiliated with Champlain Valley Physicians Hospital. The medical group on file is University of Vermont Medical Center. Dmand AI also links Dr. Perrapato to 3 more hospitals, 2 medical groups and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Perrapato practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Perrapato's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Perrapato is licensed in New York.

CMS data shows 823 Medicare services from Dr. Perrapato across 11 procedure codes in 2024, for 454 Medicare patients. Medicare paid $55,114 for them.

CMS counts 454 Medicare patients who saw Dr. Perrapato in 2024. The largest group is 75 to 84, with 206 patients. 73% of them have high cholesterol, and 70% have cancer. 10% are also on Medicaid. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Perrapato's median patient age at 75, with 17% women.

In 2024, Dr. Perrapato wrote 1,269 Medicare Part D claims for 334 patients. 98% of them were for generic drugs. CMS names the drug for 1,197 of them, across 14 drugs with 11 or more claims each, at $38,330 in total drug cost. In 2023, CMS named 1,399 claims across 15 drugs.

Dr. Perrapato accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Perrapato as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 10 papers to Dr. Perrapato, published from 2015 to 2019. The most frequent topics are Prostatic Neoplasms, MicroRNAs and Prostate-Specific Antigen. Dr. Perrapato has published most often in Crit Rev Eukaryot Gene Expr. Dr. Perrapato's most frequent co-authors are Nicholas Farina, MD, Steven Ades, MD and Brian Hilbert Irwin, MD.

Dmand AI links Dr. Perrapato to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Carcinoma, Renal Cell and Kidney Neoplasms.

CMS Open Payments shows 5 general payments to Dr. Perrapato from 2 drug and device companies from 2016 to 2025. Education make up the largest share, 60% of the total. Astellas Pharma US Inc paid the most, $293.

Dr. Perrapato graduated from Rowan University School of Osteopathic Medicine in 1982.